Targeting apoptosis pathways by natural compounds in cancer: Marine compounds as lead structures and chemical tools for cancer therapy

Cancer Letters

Volumn 332, Issue 2, 2013, Pages 295-303

  von Schwarzenberg, Karin ^a   Vollmar, Angelika M ^a  

^a Center for Drug Research   (Germany)

Author keywords

Apoptosis; Cancer; Marine compounds; Natural compounds

Indexed keywords

ANTINEOPLASTIC AGENT; ASCIDIDEMIN; BORTEZOMIB; BRYOSTATIN; BRYOSTATIN 1; CALPAIN; CASPASE 2; CASPASE 3; CASPASE 4; CEPHALOSTATIN; CEPHALOSTATIN 1; CYTOTOXIC AGENT; DISCODERMOLIDE; DISCODERMOLIDE DERIVATIVE; DOLASTATIN 10; DOLASTATIN DERIVATIVE; GEMCITABINE; KAHALALIDE F; NATURAL PRODUCT; PACLITAXEL; SALINOSPORAMIDE A; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SOBLIDOTIN; SPONGISTATIN; SPONGISTATIN 1; TRABECTEDIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER THERAPY; CONCENTRATION RESPONSE; DNA ADDUCT; DRUG CYTOTOXICITY; DRUG DNA BINDING; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVATION; HUMAN; INTRACELLULAR SIGNALING; LEUKEMIA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MARINE SPECIES; MELANOMA; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; SARCOMA; SHORT SURVEY; UNSPECIFIED SIDE EFFECT;

ACTINOBACTERIA;

EID: 84876074186     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.07.004     Document Type: Review

References (78)

1. Newman D.J., Cragg G.M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod. 2007, 70:461-477.
2. Koehn F.E., Carter G.T. The evolving role of natural products in drug discovery. Nat. Rev. Drug Discov. 2005, 4:206-220.
3. Williams P.G. Panning for chemical gold: marine bacteria as a source of new therapeutics. Trends Biotechnol. 2009, 27:45-52.
4. Simmons T.L., Andrianasolo E., McPhail K., Flatt P., Gerwick W.H. Marine natural products as anticancer drugs. Mol. Cancer Ther. 2005, 4:333-342.
5. Newman D.J., Cragg G.M. Marine natural products and related compounds in clinical and advanced preclinical trials. J. Nat. Prod. 2004, 67:1216-1238.
6. Molinski T.F., Dalisay D.S., Lievens S.L., Saludes J.P. Drug development from marine natural products. Nat. Rev. Drug Discov. 2009, 8:69-85.
7. Bergmann W. Contributions to the study of marine products XLIII. The nucleosides of sponges. V. J. Org. Chem. 1957, 22:1575-1657.
8. Schoffski P., Dumez H., Wolter P., Stefan C., Wozniak A., Jimeno J., Van Oosterom A.T. Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma. Expert Opin. Pharmacother. 2008, 9:1609-1618.
9. Martinez E.J., Corey E.J. A new, more efficient, and effective process for the synthesis of a key pentacyclic intermediate for production of ecteinascidin and phthalascidin antitumor agents. Org. Lett. 2000, 2:993-996.
10. Cuevas C., Perez M., Martin M.J., Chicharro J.L., Fernandez-Rivas C., Flores M., Francesch A., Gallego P., Zarzuelo M., de La Calle F., Garcia J., Polanco C., Rodriguez I., Manzanares I. Synthesis of ecteinascidin ET-743 and phthalascidin Pt-650 from cyanosafracin B. Org. Lett. 2000, 2:2545-2548.
11. Pommier Y., Kohlhagen G., Bailly C., Waring M., Mazumder A., Kohn K.W. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 1996, 35:13303-13309.
12. Takebayashi Y., Pourquier P., Zimonjic D.B., Nakayama K., Emmert S., Ueda T., Urasaki Y., Kanzaki A., Akiyama S.I., Popescu N., Kraemer K.H., Pommier Y. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat. Med. 2001, 7:961-966.
13. Demetri G.D., Chawla S.P., von Mehren M., Ritch P., Baker L.H., Blay J.Y., Hande K.R., Keohan M.L., Samuels B.L., Schuetze S., Lebedinsky C., Elsayed Y.A., Izquierdo M.A., Gomez J., Park Y.C., Le Cesne A. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J. Clin. Oncol. 2009, 27:4188-4196.
14. Del Campo J.M., Roszak A., Bidzinski M., Ciuleanu T.E., Hogberg T., Wojtukiewicz M.Z., Poveda A., Boman K., Westermann A.M., Lebedinsky C. Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. Ann. Oncol. 2009, 20:1794-1802.
15. Gajate C., An F., Mollinedo F. Differential cytostatic and apoptotic effects of ecteinascidin-743 in cancer cells, transcription-dependent cell cycle arrest and transcription-independent JNK and mitochondrial mediated apoptosis. J. Biol. Chem. 2002, 277:41580-41589.
16. Forni C., Minuzzo M., Virdis E., Tamborini E., Simone M., Tavecchio M., Erba E., Grosso F., Gronchi A., Aman P., Casali P., D'Incalci M., Pilotti S., Mantovani R. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol. Cancer Ther. 2009, 8:449-457.
17. Delfourne E., Bastide J. Marine pyridoacridine alkaloids and synthetic analogues as antitumor agents. Med. Res. Rev. 2003, 23:234-252.
18. Bonnard I., Bontemps N., Lahmy S., Banaigs B., Combaut G., Francisco C., Colson P., Houssier C., Waring M.J., Bailly C. Binding to DNA and cytotoxic evaluation of ascididemin, the major alkaloid from the Mediterranean ascidian Cystodytes dellechiajei. Anticancer Drug Design 1995, 10:333-346.
19. Matsumoto S.S., Biggs J., Copp B.R., Holden J.A., Barrows L.R. Mechanism of ascididemin-induced cytotoxicity. Chem. Res. Toxicol. 2003, 16:113-122.
20. Guittat L., De Cian A., Rosu F., Gabelica V., De Pauw E., Delfourne E., Mergny J.L. Ascididemin and meridine stabilise G-quadruplexes and inhibit telomerase in vitro. Biochim. Biophys. Acta 2005, 1724:375-384.
21. Dassonneville L., Wattez N., Baldeyrou B., Mahieu C., Lansiaux A., Banaigs B., Bonnard I., Bailly C. Inhibition of topoisomerase II by the marine alkaloid ascididemin and induction of apoptosis in leukemia cells. Biochem. Pharmacol. 2000, 60:527-537.
22. Dirsch V.M., Kirschke S.O., Estermeier M., Steffan B., Vollmar A.M. Apoptosis signaling triggered by the marine alkaloid ascididemin is routed via caspase-2 and JNK to mitochondria. Oncogene 2004, 23:1586-1593.
23. Pettit G.R., Tan R., Xu J., Ichihara Y., Williams M.D., Boyd M.R. Antineoplastic agents. 398. Isolation and structure elucidation of cephalostatins 18 and 19. J. Nat. Prod. 1998, 61:955-958.
24. Boyd M.R. The NCI in vitro anticancer drug discovery screen. Concept, implementation, and operation, 1985-1995. Anticancer Drug Develop. Guide - Preclin. Screen., Clin. Trials, Approval 1997, 23-42.
25. Pettit G.R., Xu J.P., Williams M.D., Christie N.D., Doubek D.L., Schmidt J.M., Boyd M.R. Isolation and structure of cephalostatins 10 and 11. J. Nat. Prod. 1994, 57:52-63.
26. Fortner K.C., Kato D., Tanaka Y., Shair M.D. Enantioselective synthesis of (+)-cephalostatin 1. J. Am. Chem. Soc. 2010, 132:275-280.
27. Rudy A., Lopez-Anton N., Dirsch V.M., Vollmar A.M. The cephalostatin way of apoptosis. J. Nat. Prod. 2008, 71:482-486.
28. Rudy A., Lopez-Anton N., Barth N., Pettit G.R., Dirsch V.M., Schulze-Osthoff K., Rehm M., Prehn J.H., Vogler M., Fulda S., Vollmar A.M. Role of Smac in cephalostatin-induced cell death. Cell Death Differ. 2008, 15:1930-1940.
29. Muller I.M., Dirsch V.M., Rudy A., Lopez-Anton N., Pettit G.R., Vollmar A.M. Cephalostatin 1 inactivates Bcl-2 by hyperphosphorylation independent of M-phase arrest and DNA damage. Mol. Pharmacol. 2005, 67:1684-1689.
30. Lopez-Anton N., Rudy A., Barth N., Schmitz M.L., Pettit G.R., Schulze-Osthoff K., Dirsch V.M., Vollmar A.M. The marine product cephalostatin 1 activates an endoplasmic reticulum stress-specific and apoptosome-independent apoptotic signaling pathway. J. Biol. Chem. 2006, 281:33078-33086.
31. Dirsch V.M., Muller I.M., Eichhorst S.T., Pettit G.R., Kamano Y., Inoue M., Xu J.P., Ichihara Y., Wanner G., Vollmar A.M. Cephalostatin 1 selectively triggers the release of Smac/DIABLO and subsequent apoptosis that is characterized by an increased density of the mitochondrial matrix. Cancer Res. 2003, 63:8869-8876.
32. Chauhan D., Hideshima T., Rosen S., Reed J.C., Kharbanda S., Anderson K.C. Apaf-1/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells. J. Biol. Chem. 2001, 276:24453-24456.
33. Altznauer F., Conus S., Cavalli A., Folkers G., Simon H.U. Calpain-1 regulates Bax and subsequent Smac-dependent caspase-3 activation in neutrophil apoptosis. J. Biol. Chem. 2004, 279:5947-5957.
34. Vaux D.L., Silke J. IAPs, RINGs and ubiquitylation. Nat. Rev. Mol. Cell Biol. 2005, 6:287-297.
35. Vogler M., Giagkousiklidis S., Genze F., Gschwend J.E., Debatin K.M., Fulda S. Inhibition of clonogenic tumor growth: a novel function of Smac contributing to its antitumor activity. Oncogene 2005, 24:7190-7202.
36. Giagkousiklidis S., Vogler M., Westhoff M.A., Kasperczyk H., Debatin K.M., Fulda S. Sensitization for gamma-irradiation-induced apoptosis by second mitochondria-derived activator of caspase. Cancer Res. 2005, 65:10502-10513.
37. O'Reilly L.A., Ekert P., Harvey N., Marsden V., Cullen L., Vaux D.L., Hacker G., Magnusson C., Pakusch M., Cecconi F., Kuida K., Strasser A., Huang D.C., Kumar S. Caspase-2 is not required for thymocyte or neuronal apoptosis even though cleavage of caspase-2 is dependent on both Apaf-1 and caspase-9. Cell Death Differ. 2002, 9:832-841.
38. Lassus P., Opitz-Araya X., Lazebnik Y. Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. Science 2002, 297:1352-1354.
39. Read S.H., Baliga B.C., Ekert P.G., Vaux D.L., Kumar S. A novel Apaf-1-independent putative caspase-2 activation complex. J. Cell Biol. 2002, 159:739-745.
40. Tinel A., Tschopp J. The PIDDosome, a protein complex implicated in activation of caspase-2 in response to genotoxic stress. Science 2004, 304:843-846.
41. Wang Q., Maniati M., Jabado O., Pavlaki M., Troy C.M., Greene L.A., Stefanis L. RAIDD is required for apoptosis of PC12 cells and sympathetic neurons induced by trophic factor withdrawal. Cell Death Differ. 2006, 13:75-83.
42. Taghiyev A.F., Guseva N.V., Glover R.A., Rokhlin O.W., Cohen M.B. TSA-induced cell death in prostate cancer cell lines is caspase-2 dependent and involves the PIDDosome. Cancer Biol. Ther. 2006, 5:1199-1205.
43. Morris J.C., Nicholas G.M., Phillips A.J. Marine natural products: synthetic aspects. Nat. Prod. Rep. 2007, 24:87-108.
44. Schyschka L., Rudy A., Jeremias I., Barth N., Pettit G.R., Vollmar A.M. Spongistatin 1: a new chemosensitizing marine compound that degrades XIAP. Leukemia 2008, 22:1737-1745.
45. Schneiders U.M., Schyschka L., Rudy A., Vollmar A.M. BH3-only proteins Mcl-1 and Bim as well as endonuclease G are targeted in spongistatin 1-induced apoptosis in breast cancer cells. Mol. Cancer Ther. 2009, 8:2914-2925.
46. Rothmeier A.S., Ischenko I., Joore J., Garczarczyk D., Furst R., Bruns C.J., Vollmar A.M., Zahler S. Investigation of the marine compound spongistatin 1 links the inhibition of PKCalpha translocation to nonmitotic effects of tubulin antagonism in angiogenesis. FASEB J. 2009, 23:1127-1137.
47. Williams P.G., Buchanan G.O., Feling R.H., Kauffman C.A., Jensen P.R., Fenical W. New cytotoxic salinosporamides from the marine Actinomycete Salinispora tropica. J. Org. Chem. 2005, 70:6196-6203.
48. Chauhan D., Catley L., Li G., Podar K., Hideshima T., Velankar M., Mitsiades C., Mitsiades N., Yasui H., Letai A., Ovaa H., Berkers C., Nicholson B., Chao T.H., Neuteboom S.T., Richardson P., Palladino M.A., Anderson K.C. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell. 2005, 8:407-419.
49. Chauhan D., Anderson K.C. Mechanisms of cell death and survival in multiple myeloma (MM): therapeutic implications. Apoptosis 2003, 8:337-343.
50. Chauhan D., Hideshima T., Anderson K.C. A novel proteasome inhibitor NPI-0052 as an anticancer therapy. Br. J. Cancer. 2006, 95:961-965.
51. Tsueng G., Lam K.S. A low-sodium-salt formulation for the fermentation of salinosporamides by Salinispora tropica strain NPS21184. Appl. Microbiol. Biotechnol. 2008, 78:821-826.
52. Pettit G.R. Progress in the discovery of biosynthetic anticancer drugs. J. Nat. Prod. 1996, 59:812-821.
53. Wender P.A., Cribbs C.M., Koehler K.F., Sharkey N.A., Herald C.L., Kamano Y., Pettit G.R., Blumberg P.M. Modeling of the bryostatins to the phorbol ester pharmacophore on protein kinase C. Proc. Natl. Acad. Sci. USA 1988, 85:7197-7201.
54. Isakov N., Galron D., Mustelin T., Pettit G.R., Altman A. Inhibition of phorbol ester-induced T cell proliferation by bryostatin is associated with rapid degradation of protein kinase C. J. Immunol. 1993, 150:1195-1204.
55. Kortmansky J., Schwartz G.K. Bryostatin-1: a novel PKC inhibitor in clinical development. Cancer Invest. 2003, 21:924-936.
56. Ali S., Aranha O., Li Y., Pettit G.R., Sarkar F.H., Philip P.A. Sensitization of human breast cancer cells to gemcitabine by the protein kinase C modulator bryostatin 1. Cancer Chemother. Pharmacol. 2003, 52:235-246.
57. Koutcher J.A., Motwani M., Zakian K.L., Li X.K., Matei C., Dyke J.P., Ballon D., Yoo H.H., Schwartz G.K. The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow. Clin. Cancer Res. 2000, 6:1498-1507.
58. Kornblau S.M., Konopleva M., Andreeff M. Apoptosis regulating proteins as targets of therapy for haematological malignancies. Expert Opin. Investig. Drugs 1999, 8:2027-2057.
59. Wang S., Wang Z., Boise L.H., Dent P., Grant S. Bryostatin 1 enhances paclitaxel-induced mitochondrial dysfunction and apoptosis in human leukemia cells (U937) ectopically expressing Bcl-xL. Leukemia 1999, 13:1564-1573.
60. Pettit G.R. The dolastatins. Fortschr. Chem. Org. Naturst 1997, 70:1-79.
61. Bai R., Pettit G.R., Hamel E. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem. Pharmacol. 1990, 39:1941-1949.
62. Sato M., Sagawa M., Nakazato T., Ikeda Y., Kizaki M. A natural peptide, dolastatin 15, induces G2/M cell cycle arrest and apoptosis of human multiple myeloma cells. Int. J. Oncol. 2007, 30:1453-1459.
63. Kalemkerian G.P., Ou X., Adil M.R., Rosati R., Khoulani M.M., Madan S.K., Pettit G.R. Activity of dolastatin 10 against small-cell lung cancer in vitro and in vivo: induction of apoptosis and bcl-2 modification. Cancer Chemother. Pharmacol. 1999, 43:507-515.
64. Wall N.R., Mohammad R.M., Al-Katib A.M. Bax:Bcl-2 ratio modulation by bryostatin 1 and novel antitubulin agents is important for susceptibility to drug induced apoptosis in the human early pre-B acute lymphoblastic leukemia cell line. Reh, Leuk. Res. 1999, 23:881-888.
65. Kobayashi M., Natsume T., Tamaoki S., Watanabe J., Asano H., Mikami T., Miyasaka K., Miyazaki K., Gondo M., Sakakibara K., Tsukagoshi S. Antitumor activity of TZT-1027, a novel dolastatin 10 derivative. Jpn. J. Cancer Res. 1997, 88:316-327.
66. De Souza M.V. (+)-discodermolide: a marine natural product against cancer. ScientificWorldJournal 2004, 4:415-436.
67. Longley R.E., Gunasekera S.P., Faherty D., McLane J., Dumont F. Immunosuppression by discodermolide. Ann. NY Acad. Sci. 1993, 696:94-107.
68. Hung D.T., Chen J., Schreiber S.L. (+)-Discodermolide binds to microtubules in stoichiometric ratio to tubulin dimers, blocks taxol binding and results in mitotic arrest. Chem. Biol. 1996, 3:287-293.
69. Martello L.A., McDaid H.M., Regl D.L., Yang C.P., Meng D., Pettus T.R., Kaufman M.D., Arimoto H., Danishefsky S.J., Smith A.B., Horwitz S.B. Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines. Clin. Cancer Res. 2000, 6:1978-1987.
70. Khrapunovich-Baine M., Menon V., Verdier-Pinard P., Smith A.B., Angeletti R.H., Fiser A., Horwitz S.B., Xiao H. Distinct pose of discodermolide in taxol binding pocket drives a complementary mode of microtubule stabilization. Biochemistry 2009, 48:11664-11677.
71. Broker L.E., Huisman C., Ferreira C.G., Rodriguez J.A., Kruyt F.A., Giaccone G. Late activation of apoptotic pathways plays a negligible role in mediating the cytotoxic effects of discodermolide and epothilone B in non-small cell lung cancer cells. Cancer Res. 2002, 62:4081-4088.
72. Broker L.E., Huisman C., Span S.W., Rodriguez J.A., Kruyt F.A., Giaccone G. Cathepsin B mediates caspase-independent cell death induced by microtubule stabilizing agents in non-small cell lung cancer cells. Cancer Res. 2004, 64:27-30.
73. Hamann M.T., Otto C.S., Scheuer P.J., Dunbar D.C. Kahalalides: bioactive peptides from a marine mollusk elysia rufescens and its algal diet Bryopsis sp. (1). J. Org. Chem. 1996, 61:6594-6600.
74. Lopez-Macia A., Jimenez J.C., Royo M., Giralt E., Albericio F. Synthesis and structure determination of kahalalide F (1, 2). J. Am. Chem. Soc. 2001, 123:11398-11401.
75. Janmaat M.L., Rodriguez J.A., Jimeno J., Kruyt F.A., Giaccone G. Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling. Mol. Pharmacol. 2005, 68:502-510.
76. Suarez Y., Gonzalez L., Cuadrado A., Berciano M., Lafarga M., Munoz A. Kahalalide F, a new marine-derived compound, induces oncosis in human prostate and breast cancer cells. Mol. Cancer Ther. 2003, 2:863-872.
77. Garcia-Rocha M., Bonay P., Avila J. The antitumoral compound Kahalalide F acts on cell lysosomes. Cancer Lett. 1996, 99:43-50.
78. Jimeno J., Lopez-Martin J.A., Ruiz-Casado A., Izquierdo M.A., Scheuer P.J., Rinehart K. Progress in the clinical development of new marine-derived anticancer compounds. Anticancer Drugs 2004, 15:321-329.